INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32301, 14314, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32302, 15147, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32303, 15148, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32304, 15162, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32305, 15163, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32306, 15177, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32307, 15178, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32308, 18465, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32309, 25194, 'Betaxolol', 'Myocardial Ischemia', 'Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers).  Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy.  Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency.  Patients should be advised not to discontinue treatment without first consulting with the physician.  In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32310, 1485, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32311, 14314, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32312, 15147, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32313, 15148, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32314, 15162, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32315, 15163, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32316, 15177, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32317, 15178, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32318, 18465, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32319, 25194, 'Betaxolol', 'Peripheral Vascular Diseases', 'Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.  In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels.  Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease.  Close monitoring for progression of arterial obstruction is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32320, 1485, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32321, 14314, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32322, 15147, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32323, 15148, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32324, 15162, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32325, 15163, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32326, 15177, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32327, 15178, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32328, 18465, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32329, 25194, 'Betaxolol', 'Kidney Diseases', 'Betaxolol and its metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from betaxolol due to decreased drug clearance.  Therapy with betaxolol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with severe renal dysfunction (CrCl < 10 mL/min) or undergoing dialysis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32330, 1485, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32331, 14314, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32332, 15147, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32333, 15148, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32334, 15162, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32335, 15163, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32336, 15177, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32337, 15178, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32338, 18465, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32339, 25194, 'Betaxolol', 'Cerebrovascular Disorders', 'Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32340, 1485, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32341, 14314, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32342, 15147, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32343, 15148, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32344, 15162, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32345, 15163, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32346, 15177, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32347, 15178, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32348, 18465, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32349, 25194, 'Betaxolol', 'Glaucoma', 'Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32350, 1485, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32351, 14314, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32352, 15147, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32353, 15148, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32354, 15162, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32355, 15163, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32356, 15177, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32357, 15178, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32358, 18465, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32359, 25194, 'Betaxolol', 'Hyperlipidemias', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32360, 1485, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32361, 14314, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32362, 15147, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32363, 15148, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32364, 15162, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32365, 15163, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32366, 15177, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32367, 15178, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32368, 18465, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32369, 25194, 'Betaxolol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32370, 1485, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32371, 14314, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32372, 15147, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32373, 15148, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32374, 15162, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32375, 15163, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32376, 15177, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32377, 15178, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32378, 18465, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32379, 25194, 'Betaxolol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32380, 1485, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32381, 14314, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32382, 15147, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32383, 15148, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32384, 15162, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32385, 15163, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32386, 15177, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32387, 15178, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32388, 18465, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32389, 25194, 'Betaxolol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32390, 1485, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32391, 14314, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32392, 15147, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32393, 15148, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32394, 15162, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32395, 15163, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32396, 15177, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32397, 15178, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32398, 18465, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32399, 25194, 'Betaxolol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (32400, 1485, 'Betaxolol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '', 'DDInter', 0);
